DelveInsight’s “Polycythemia Vera – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Polycythemia Vera market share of the individual therapies, current and forecasted Polycythemia Vera market size from 2019 to 2032 segmented by seven major markets. The report also offers current Polycythemia Vera therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Polycythemia Vera market.
Key Takeaways from the Polycythemia Vera Market Report
- According to DelveInsight estimates, the total market size of Polycythemia Vera in the 7MM is approximately USD 1,800 million in 2022 and is projected to increase during the forecast period (2023-2032).
- As per the assessment done by DelveInsight, the total prevalent cases of Polycythemia Vera in the 7MM comprised of approximately 309K cases in 2022 and are projected to increase during the forecasted period.
- Leading Polycythemia Vera companies such as Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, and others are developing novel Polycythemia Vera drugs that can be available in the Polycythemia Vera market in the upcoming years.
- Promising Polycythemia Vera therapies in the pipeline include Rusfertide (PTG-300), Bomedemstat (IMG-7289), Givinostat (ITF2357), Sapablursen (IONIS-TMPRSS6-LRx), SLN124, PPMX-T003, and others.
Discover more about therapies set to grab major Polycythemia Vera market share @ Polycythemia Vera Market Report
Polycythemia Vera Overview
Polycythemia Vera (PV) is a condition that causes an increase in the number of red blood cells in the bloodstream (erythrocytosis), as well as an increase in white blood cells and platelets. The majority of cases of Polycythemia Vera are acquired during a person’s lifetime rather than inherited. Polycythemia Vera is typically diagnosed in people between the ages of 60 and 65. It is extremely rare in people under the age of 40. Polycythemia Vera occurs more frequently in men than in women.
Polycythemia Vera symptoms include headache, dizziness, fatigue, blurred vision or blind spots, shortness of breath, itchy skin, spleen enlargement (Splenomegaly), blood clot, heavy bleeding, and others. The most dangerous symptom of polycythemia vera is the possibility of a thrombotic event, which can result in a heart attack or stroke.
Learn more about the Polycythemia Vera treatment guidelines @ Polycythemia Vera Guidelines
Polycythemia Vera Epidemiological Insights
As per DelveInsight, the total prevalent cases of Polycythemia Vera in the 7MM was approx 309K in 2022.
Among the 7MM, the United States contributed to the largest prevalent population of Polycythemia Vera, acquiring ~58% of the 7MM in 2022.
The Polycythemia Vera market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total prevalent cases
- Prevalent population of Polycythemia Vera based on symptoms
- Gender-specific cases
- Prevalence of Polycythemia Vera by gene mutation
- Prevalence of Polycythemia Vera based on risk
- Age-specific prevalence
Download the report to understand which factors are driving Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiological Insights
Polycythemia Vera Treatment Market
Polycythemia Vera can be treated using a variety of methods, including phlebotomy, hydroxyurea, low-dose aspirin, ruxolitinib, hypouricemic agents, antihistamines, and serotonin reuptake inhibitors (SSRIs). The Polycythemia Vera Study Group (PVSG) trial established phlebotomy as the backbone of therapy. It is also known as venesection, a major therapeutic procedure physicians perform in various civilizations. Low-risk patients who cannot tolerate phlebotomy, have severe disease-related symptoms or progressive splenomegaly, or have platelet counts >1500 109/L or progressive leukocytosis should also be considered for cytoreductive therapy.
Aspirin is both an antiplatelet and a pain reliever. If the platelet count rises, this can be effective. Higher doses of aspirin or dipyridamole resulted in unsatisfactory gastrointestinal hemorrhage in early trials, but lower doses of aspirin (40-100 mg daily) resulted in good results. To reduce blood cell production in the bone marrow, myelosuppressive (bone marrow suppressing) drugs or chemotherapy are commonly used. These drugs are widely used for people with an extremely high platelet count, which causes complications such as blood clotting or bleeding and symptoms such as an enlarged spleen.
To know more about Polycythemia Vera treatment options, visit @ Polycythemia Vera Drugs
Polycythemia Vera Pipeline Therapies
- Rusfertide (PTG-300)
- Bomedemstat (IMG-7289)
- Givinostat (ITF2357)
- Sapablursen (IONIS-TMPRSS6-LRx)
- SLN124
- PPMX-T003
Polycythemia Vera Key Companies
- Protagonist Therapeutics
- Imago BioSciences
- Italfarmaco
- Ionis Pharmaceutical
- Silence Therapeutics
- Perseus Proteomics
Learn more about the Polycythemia Vera therapies in clinical trials @ New Treatment for Polycythemia Vera
Polycythemia Vera Market Dynamics
The dynamics of the Polycythemia Vera market are expected to change in the coming years as research and development activities improve and more efficient treatment options become available in the market. Moreover, the recent approval of Besremi in the United States and its expected approval in Japan provide the interferon with an enormous opportunity to gain a large Polycythemia Vera market share. Based on its increasing sales, we expected Jakafi to be a blockbuster treatment in 2L PV patients. Furthermore, emerging drugs with novel mechanisms of action, such as givinostat (HDAC inhibitor), rusfertide (Iron modulator), KRT-232 (MDM2 inhibitor), and bomedemstat (Lysine-specific Demethylase 1 [LSD1 or KDM1A] Inhibitor), have the potential to address the unmet need.
However, certain factors are impeding the growth of the Polycythemia Vera market. Patients undergoing phlebotomy may develop iron deficiency, which frequently causes fatigue and may result in reactive thrombocytosis. HU (hydroxyurea) resistance in PV patients can increase the risk of death and progression to MF. Low platelet or red blood cell counts are common side effects of Jakafi, and the FDA has issued a black box warning on JAK inhibitors. The overall cost of Polycythemia Vera treatment is quite high, which raises patients’ out-of-pocket costs and places an economic burden on patients and their families.
Scope of the Polycythemia Vera Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain)], the United Kingdom), and Japan
- Key Polycythemia Vera Companies: Protagonist Therapeutics (NASDAQ: PTGX), Imago BioSciences, Italfarmaco, Ionis Pharmaceutical (NASDAQ: IONS), Silence Therapeutics (NASDAQ: SLN), Perseus Proteomics, and others
- Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Bomedemstat (IMG-7289), Givinostat (ITF2357), Sapablursen (IONIS-TMPRSS6-LRx), SLN124, PPMX-T003, and others
- Therapeutic Assessment: Polycythemia Vera current marketed and emerging therapies
- Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Polycythemia Vera Market Access and Reimbursement
Discover more about Polycythemia Vera drugs in development @ Polycythemia Vera Clinical Trials
Table of Contents
| 1. | Polycythemia Vera Market Key Insights |
| 2. | Polycythemia Vera Market Report Introduction |
| 3. | Polycythemia Vera Market Overview at a Glance |
| 4. | Polycythemia Vera Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Polycythemia Vera Treatment and Management |
| 7. | Polycythemia Vera Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Polycythemia Vera Marketed Drugs |
| 10. | Polycythemia Vera Emerging Drugs |
| 11. | Seven Major Polycythemia Vera Market Analysis |
| 12. | Polycythemia Vera Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Polycythemia Vera Market Drivers |
| 16. | Polycythemia Vera Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Get in touch with our Business executive @ Healthcare Consulting Services
Related Reports
Polycythemia Vera Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Polycythemia Vera companies, including Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Sanofi, Roche, among others.
Post-Polycythemia Vera Myelofibrosis Market
Post-Polycythemia Vera Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Post-Polycythemia Vera Myelofibrosis companies, including Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Imago BioSciences, Inc., Hoffmann-La Roche, among others.
Post-Polycythemia Vera Myelofibrosis Pipeline
Post-Polycythemia Vera Myelofibrosis Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Post-Polycythemia Vera Myelofibrosis companies, including Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Imago BioSciences, Inc., Hoffmann-La Roche, among others.
Polycythemia Vera Epidemiology
Polycythemia Vera Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Polycythemia Vera epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Post-Polycythemia Vera Myelofibrosis Epidemiology
Post-Polycythemia Vera Myelofibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Post-Polycythemia Vera Myelofibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Other Trending Reports:
- Apraxia Market
- Hip Replacement Devices Market
- Global Electrophysiology Devices Market
- Acute Radiation Syndrome Market
- Bronchial Spasm Market
- Interbody Cages Market
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Sandeep Joshi
+1(919)321-6187